Propranolol disposition in chronic liver disease: a physiological approach.
The pharmacokinetics of propranolol can be quantitatively explained on a physiological basis from a knowledge of the effects of four biological determinants: (1) the activity of the drug metabolising enzymes (intrinsic clearance); (2) hepatic blood flow; (3) drug binding, and (4) the anatomical arrangement of the hepatic circulation. Distrubances of all these determinants can occur in chronic liver disease and result in predictable changes in propranolol disposition. These changes, as well as those occurring with other drugs in chronic liver may be explained by 'intact hepatocyte theory' which postulates that the major pathophysiological change occurring in compensated chronic liver disease is a reduction in relatively normally perfused and functioning cell mass with the development of intrahepatic portasystemic vascular shunts.
D000284:Administration, Oral; D001798:Blood Proteins / Q000378:metabolism; D002908:Chronic Disease; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000503:physiopathology; D008107:Liver Diseases / Q000378:metabolism* / Q000503:physiopathology; D011167:Portacaval Shunt, Surgical; D011433:Propranolol / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D011485:Protein Binding
D001798:Blood Proteins; D011433:Propranolol